Eclipse Axcis PTMR Clinical Data Could Bring Approval In September
This article was originally published in The Gray Sheet
Executive Summary
Eclipse Surgical expects the PMA for its Axcis percutaneous transmyocardial revascularization (PTMR) device to receive less resistance from FDA's Circulatory System Devices Advisory Panel than was encountered in the review of the company's TMR product in 1998.
You may also be interested in...
Postmarket Surveillance Orders Expected To Follow Final Rule
The Center for Devices and Radiological Health plans to issue new orders for postmarket surveillance in several device areas soon after issuing a final rule on the Safe Medical Devices Act Sec. 522 provision.
BELIEF Data May Dispel "Placebo Effect" Shadow Over Eclipse PTMR
Results from the "Blinded Evaluation of Laser 'PTMR' Intervention Electively For angina pectoris" (BELIEF) trial may represent a key step in restoring faith in the clinical efficacy of percutaneous transmyocardial revascularization and dispelling doubts raised that the therapy has no benefits beyond a placebo effect.
Eclipse's PACIFIC Trial Suggests Improved Outcomes For PTMR Patients
Eclipse Surgical's PACIFIC trial evaluating percutaneous transmyocardial revascularization (PTMR) for refractory angina shows a significant increase in patients' exercise tolerance, but leaves open the question of whether or not they experience a placebo effect from the procedure.